Journals / Cukurova Medical Journal / 2023 / Cilt: 48 Sayı: 2

Comparison of gene expressions in individuals with G6PD Mediterranean mutation and hemolytic anemia

G6PD Akdeniz mutasyonu olan hemolitik anemili bireylerde gen ekspresyonlarının karşılaştırılması

Pages
351–360
Publication Date
2023-07-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a further study, the decrease in gene expressions of patients with hemolytic anemia with Gd-Med mutation can be clarified by evaluating the promoter side of the gene.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In our study, we aimed to clarify the relationship between Glucose-6-phosphate dehydrogenase (G6PD) enzyme kinetics and mRNA expression levels of the G6PD gene in Gd-Med patients with and without hemolytic anemia.
📊
Key Findings & Data:Materials and Methods: The study group consisted of 30 cases with Gd-Med mutation and 30 cases with enzyme activity levels in the reference range.
💡
Conclusion & Impact:As a further study, the decrease in gene expressions of patients with hemolytic anemia with Gd-Med mutation can be clarified by evaluating the promoter side of the gene.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Enzim Kinetiği · Gen Ekspresyonu · Glukoz-6-fosfat Dehidrogenaz

Abstract

Purpose: In our study, we aimed to clarify the relationship between Glucose-6-phosphate dehydrogenase (G6PD) enzyme kinetics and mRNA expression levels of the G6PD gene in Gd-Med patients with and without hemolytic anemia. Materials and Methods: The study group consisted of 30 cases with Gd-Med mutation and 30 cases with enzyme activity levels in the reference range. G6PD activity was determined by the Beutler method. G6PD enzyme was partially purified with DE-52 anion exchange resin, and its kinetic parameters were studied. Gd-Med mutation was genotyped by MboII enzyme digest and sequence analysis. The expression level of the G6PD gene was calculated according to the 2-ΔΔCt formula. Results: In our study, a significant difference was found between the KmNADP+ and KmG6P values of the cases with Gd-Med mutation and the control group. There was no significant difference between KmNADP+ and KmG6P values in Gd-Med mutated patients with and without hemolytic anemia. Gene expression results of 18 patients without hemolytic anemia were significantly higher than 12 patients with hemolytic anemia. In addition, there was a significant difference between these variables and the control group. Conclusion: It might be a possible explanation that the substrate binding site of the enzyme in cases with Gd-Med mutation may have undergone post-transcriptional or post-translational modifications, and therefore gene expression might be changed. As a further study, the decrease in gene expressions of patients with hemolytic anemia with Gd-Med mutation can be clarified by evaluating the promoter side of the gene.

Özet

Amaç: Çalışmamızda, Gd-Akdeniz’li bireylerde hemolitik anemisi olan ve olmayan olguların Glukoz-6-fosfat dehidrogenaz (G6PD) enzimi kinetiği ve G6PD geninin mRNA ekspresyon seviyeleri arasındaki ilişkinin irdelenerek bu duruma açıklık getirmeyi hedefledik. Gereç ve Yöntem: Çalışma grubu, Gd-Akdeniz mutasyonu bulunan 30 olgu ve enzim aktivite düzeyi referans aralığında olan 30 olgudan oluşmaktadır. G6PD aktivitesi Beutler yöntemi ile tayin edilmiştir. G6PD enzimi DE-52 anyon değiştirici reçine ile kısmi olarak saflaştırılarak kinetik özellikleri çalışılmıştır. MboII enzim kesimi ve sekans analizi ile Gd-Akdeniz mutasyonu genotiplendirilmiştir. G6PD geninin ekspresyon seviyesi 2-ΔΔCt formülüne göre hesaplanmıştır. Bulgular: Çalışmamızda Gd-Akdeniz mutasyonu bulunan olguların KmNADP+ ve KmG6P değerleri ile G6PD enzim aktivitesi referans değerlerde olan olgular arasında anlamlı düzeyde fark bulundu. Hemolitik anemisi olan ve olmayan Gd-Akdeniz mutasyonuna sahip olguların ise KmNADP+ ve KmG6P değerleri arasında anlamlı fark bulunamadı. Hemolitik anemisi olmayan 18 hastanın gen ekspresyon sonuçları, hemolitik anemisi olan 12 hastaya göre anlamlı derecede yüksek olduğu görüldü. Ayrıca enzim aktivite düzeyi referans aralığında olan olgularla da bu değişkenler kıyaslandığında yine anlamlı farklılık olduğu belirlendi Sonuç: Gd-Med mutasyonu olan olgularda enzimin substrat bağlanma bölgesinin post-transkripsiyonel veya post-translasyonel modifikasyonlara uğramış olması ve bu nedenle gen ekspresyonunun değişmesi olası bir açıklama olabilir. İleri çalışma olarak Gd-Akdeniz mutasyonuna sahip hemolitik anemisi bulunan olguların gen ekspresyonlarındaki azalmayı geninin promotör bölgesi değerlendirilerek açıklık getirilebilir.

🔖

Cite This Article

GÜNAŞTI, B., TULİ, A. (2023). Comparison of gene expressions in individuals with G6PD Mediterranean mutation and hemolytic anemia. Cukurova Medical Journal, Cilt: 48 Sayı: 2, 351–360. https://ajindex.com/articles/954992

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ghergurovich JM, Garcia-Canaveras JC, Wang J, Schmidt E, Zhang Z, Teslaa T et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nat Chem Biol. 2020;16:731–9.
  2. Jacobasch G, Rapoport SM. Hemolytic anemias due to erythrocyte enzyme deficiencies. Mol Aspects Med. 1996;17:143–70.
  3. Martini G, Toniolo D, Vulliamy T, Luzzatto L, Dono R, Viglietto G et al. Structural analysis of the X-linked gene encoding human glucose 6-phosphate dehydrogenase. EMBO J. 1986;5:1849–55.
  4. Corcoran CM, Calabro V, Tamagnini G, Town M, Haidar B, Vulliamy TJ et al. Molecular heterogeneity underlying the G6PD mediterranean phenotype. Hum Genet. 1992;88:688-90.
  5. Özer N, Aksoy Y, Ögüs IH. Kinetic properties of human placental glucose-6-phosphate dehydrogenase. Int J Biochem Cell Biol. 2001;33:221–6.
  6. Sheikh MH, Hazazi ASJ, Alanazi ANO, Hazazi ISJ, Qaysi AAM, Alali YA et al. Overview on causes and updated management of favism. J Pharm Res Int. 2021;33:249-54.
  7. Arunachalam AK, Sumithra S, Maddali M, Fouzia NA, Abraham A, George B et al. Molecular characterization of G6PD deficiency: Report of three novel G6PD variants. Indian J Hematol Blood Transfus. 2020;36:349-55. Tuli A. Çukurova'da saptanan G6PD varyantlarının mutasyon noktalarının moleküler düzeyde saptanması (Doktora tezi). Adana, Çukurova Üniversitesi, 1994.
  8. Gomez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, Serrano-Posada H, Ortega-Cuellar D, Gonzalez-Valdez A et al. Glucose-6-phosphate dehydrogenase: Update and analysis of new mutations around the world. Int J Mol Sci. 2016;17:2069.
  9. Sirdah M, Reading NS, Vankayalapati H, Perkins SL, Shubair ME, Aboud L et al. Molecular heterogeneity of glucose-6-phosphate dehydrogenase deficiency in Gaza Strip palestinians. Blood Cells Mol Dis. 2012;49:152–8. Aslan KS. Diyarbakır bölgesinde G6PD özellikleri bilinmeyen kişilerde G6PD canton, kaiping ve gaohe mutant allellerinin belirlenmesi (Yüksek lisans tezi). Diyarbakır, Dicle Üniversitesi, 2011. Beutler E. G6PD: Population genetics and clinical manifestations. Blood Rev. 1996;10:45-52.
  10. Schwartz AG, Pashko LL. Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004;3:171–87. Yoshida A. Hemolytic anemia and G6PD deficiency. Science. 1973;179:532–7.
  11. El-Deen ZME, Hussin NF, Hamid TAA, Migeed ORA, Samy RM. G6PD deficiency and G6PD (mediterranean and silent) polymorphisms in Egyptian infants with neonatal hyperbilirubinemia. Lab Med. 2013;44:228–34.
  12. Farhud DD, Yazdanpanah L. Glucos